Fig. 9.

Therapeutic targeting of Tie2 signaling using AKB-9785 in WT mice subjected to tMCAO. a TTC staining after tMCAO (3/group) showed significantly smaller infarcts 24 h post-stroke upon AKB-9785 treatment (n = 13). b An mNSS behavioral analysis of control and mice treated with AKB-9785 (30 mg/kg) showed a neurological improvement in treated mice 72 h after stroke incidence (24 h: control n = 8, AKB-9785 n = 9; 72 h: control n = 7, AKB-9785 n = 9). The neurological deficit scoring is described in “Materials and methods” and is composed of testing flexion, gait, coordination and sensory functions. The total scoring included all four behavioral tests (2-tailed unpaired non-parametric Mann–Whitney test). c IgG staining showed significantly lower permeability in AKB-9785 treated mice (n = 6). d Western blots of stroke hemisphere showed increased Akt activation in AKB-9785-treated mice (n = 7). e Tie2/pTie2 staining of the stroke hemisphere revealed significantly higher pTie2, but not total Tie2 levels in AKB-9785-treated animals (n = 5)